Mustang Bio Inc (MBIO)

US · Healthcare · Biotechnology

$0.59+3.02%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-955,000

Profit YoY

-524.2%

EPS

$-0.14

Market cap

$4.3M

Forward P/E

0.0

P/B

0.51

Book value

$1.14

EPS (TTM)

$-0.48

52-week high

$1.88

52-week low

$0.53

50-day MA

$0.67

200-day MA

$0.93

Beta

2.05

Analysts rate Mustang Bio Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Insiders

8.02%

Institutions

9.78%

Fund	Stake
Kestra Advisory Services, LLC	2.60%
Geode Capital Management, LLC	1.22%
BlackRock Inc	1.12%
Citadel Advisors Llc	0.70%
Vanguard Fiduciary Trust Co	0.42%
Vanguard Capital Management, LLC	0.34%
CFO4Life Group, LLC	0.27%
Two Sigma Investments LLC	0.22%

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mustang Bio Inc — free to start.

Data updated 2026-08-05.